Introduction {#Sec1}
============

Glaucoma is a significant medical and social issue in many countries including Russia and Japan. Glaucoma reduces the quality of life of a patient, and represent one of the major causes of blindness worldwide^[@CR1]^. Glaucoma covers a large group of ocular diseases sharing similar clinical, pathogenic and pathomorphological features. When the eyes suffer from glaucoma, the intraocular pressure (IOP) permanently or occasionally exceeds a level of tolerance, distinctive optic disk (OD) changes and ganglion cell degeneration (glaucomatous optic neuropathy) develop, leading to associated ocular dysfunction. Glaucoma may develop at different ages starting from birth, but its incidence increases with age^[@CR1],[@CR2]^. Glaucoma is classified into specific types: congenital, primary glaucoma, and secondary glaucoma. Congenital glaucoma is related to fetus disorders and birth injuries. Primary glaucoma has a multifactorial nature and is associated with age-related (involutional) changes in the eyes. Primary glaucoma is classified into primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG), the former being further classified into normal-tension glaucoma (NTG) and high-tension glaucoma (HTG). Secondary glaucoma (e.g., neovascular glaucoma) is caused by another ocular or somatic pathology. Among risk factors for glaucoma are elderly age, heredity (excess disease incidence associated with familial group), vascular factors (increased or decreased blood pressure, atherosclerosis), and endocrine disorders (diabetes mellitus, abnormal glucocorticoid metabolism)^[@CR3],[@CR4]^.

Local ocular or head and neck therapeutic irradiation at high doses (\>about 40--50 Gy) is known to increase risk of secondary glaucoma (mostly, neovascular)^[@CR5]--[@CR11]^. Studies of atomic bomb survivors acutely exposed to radiation at high dose rates demonstrated increased risk only for primary open angular normal tension glaucoma only^[@CR12],[@CR13]^. A recently published study of US radiologic technologists (USRT) showed no significant association of glaucoma with occupational radiation at low doses^[@CR14]^. Therefore, a question of whether ionizing radiation induces glaucoma development remains open and other radiation exposed cohort studies are needed to replicate the observed results. This study aims to estimate primary glaucoma incidence risk in Mayak PA workers occupationally exposed to chronic radiation at low dose rates for prolonged periods.

Methods {#Sec2}
=======

Study population and follow-up {#Sec3}
------------------------------

The Mayak Production Association (PA) is the first large-scale Russian nuclear enterprise. It is located in the Southern Urals close to the city of Ozyorsk and started its operation in 1948.

The study cohort included all workers of the enterprise first employed at one of the main facilities (reactors, radiochemical and plutonium production plants) in 1948--1982 (the mean calendar year of employment was 1959.4 ± 9.8 years), who were followed up until the end of 2008: there were a total of 22,377 individuals (of whom 25.4% were females). As for start of employment, the mean and standard deviations of age was 24.9 ± 7.5 years (min--max: 17--65 years). Duration of employment at the Mayak PA was 17.9 ± 14.1 years and ranged from 1 month up to 60 years. Only 4.70% of workers were employed at the Mayak PA less than 1 year.

The cohort follow-up started from the date of first employment at one of the main facilities and ended at the earliest of the following dates: disease diagnosis, date of death, 31 December 2008 for alive workers still residing in Ozyorsk ('residents'), date of 'the last medical information' for workers-residents with an unknown vital status and for those who had left Ozyorsk ('migrants'). The main characteristics of the study cohort are presented in Tables [1](#Tab1){ref-type="table"} and [S1](#MOESM1){ref-type="media"}. By the end of the follow-up period, a vital status was available for 95.0% of the study cohort members with 53.5% deceased and 46.5% alive.Table 1Study cohort characteristics.CharacteristicsMalesFemalesBothNumber of workers included in the cohort16,6885,68922,377Total primary glaucoma cases315161476POAG cases307154461PYR (Total primary glaucoma incidence)383,262160,974544,236PYR (POAG incidence)383,188160,874544,062Mean age at diagnosis of total primary glaucoma (SD), years64.6 (8.5)69.0 (8.8)66.1 (8.8)Mean age at diagnosis of POAG (SD), years64.6 (8.4)69.4 (8.3)66.2 (8.7)Migrated from Ozyorsk as of 31 December 20057,198 (41.1%)2,014 (35.4%)9,212 (41.1%)Vital status known as of 31 December 2008, of them:15,870 (95.1%)5,436 (95.6%)21,267 (95.0%)  Died8,954 (56.4%)2,417 (44.5%)11,371 (53.5%)  Alive6,916 (43.6%)3,019 (55.5%)9,896 (46.5%)Incidence data available16,233 (97.3%)5,530 (97.2%)21,763 (97.3%)Smoking status available, of them:15,636 (93.7%)5,270 (92.6%)20,906 (93.4%)  Known data on qualitative parameters of smoking11,064 (70.8%)5,172 (98.1%)16,236 (77.7%)Data on alcohol consumption available14,857 (89.0%)5,173 (90.9%)20,030 (89.5%)Data on hypertension available15,110 (90.5%)4,984 (87.6%)20,094 (89.8%)Data on body mass index13,732 (82.3%)4,660 (81.9%)18,392 (82.2%)Mean age at first employment (SD), years24.1 (7.1)27.3 (8.0)24.9 (7.5)Mean calendar year at first employment (SD), calendar years1959.8 (9.8)1958.0 (10.4)1959.4 (9.8)Mean duration of employment at the Mayak PA (SD), years18.3 (14.8)17.4 (12.8)17.9 (14.1)Mean age at death for workers known to have died (SD), years60.2 (13.6)68.5 (12.4)62.00 (13.8)Mean age of workers known to be alive (SD), years66.5 (10.1)74.8 (9.3)68.8 (11.5)Mean age as of migration date (SD), years31.2 (10.2)34.2 (11.9)31.6 (10.3)Mean cumulative brain absorbed dose from external γ-rays (SD), Gy^a^0.46 (0.67)0.36 (0.56)0.44 (0.65)Workers without neutron exposure13,213 (79.2%)5,081 (89.3%)18,294 (81.8%)Workers with neutron exposure3,475 (20.8%)608 (10.7%)4,083 (18.2%)  Mean cumulative brain absorbed dose from neutrons (SD), Gy^b^0.0016 (0.0043)0.0016 (0.0050)0.0016 (0.0044)The unweighted sum of mean cumulative brain absorbed γ + neutrons dose (SD), Gy^a^0.46 (0.67)0.37 (0.56)0.44 (0.65)*Notes:* POAG, primary open-angle glaucoma. PYR, person years at risk. SD, standard deviation. PA, production association.^a^For all workers.^b^For workers with neutron exposure.

All glaucoma cases were retrospectively coded according to the International Classification of Diseases, ninth revision (ICD-9)^[@CR15]^. All (total 634) cases of glaucoma (ICD-9: 365.0--365.9) diagnosed in members of the study cohort were identified using the medical and dosimetry database 'Clinic'^[@CR16]^ regardless of its type. Glaucoma was diagnosed by a qualified ophthalmologist based on generally accepted criteria (complaints, measurements of IOP, eye fundus examination, visual field tests, and gonioscopy). Of 634 cases, 476 cases (75.1%) were primary glaucoma, comprising 461 cases (96.8%) of POAG and 15 cases (3.2%) of PACG. The study outcomes included these 476 cases of primary glaucoma, because secondary glaucoma (158 cases) occurs as complications accompanying an ocular or somatic pathology.

Dosimetry {#Sec4}
---------

For analyses, absorbed doses from external γ-rays and neutrons were used based on the Mayak Worker Dosimetry System 2008 (MWDS--2008)^[@CR17]^. MWDS--2008 provides absorbed doses in 18 organs and tissues (lungs, red bone marrow, breast, bladder, kidney, skin, stomach, gonads (ovaries/testicles), thyroid, uterus, esophagus, bone surface, skeleton, liver, small intestine, large intestine, spleen), but eye dose is not available. This study therefore used individual brain absorbed doses from external γ-rays and neutrons^[@CR18]^. It should be noted that there is no considerable difference among types of organ absorbed doses from external radiation. Mean cumulative brain absorbed dose from external γ-rays was 0.46 ± 0.67 Gy in males and 0.36 ± 0.56 Gy in females. Only 4083 Mayak PA workers (18.2%) were exposed to neutrons. For these workers, the mean cumulative brain absorbed external radiation dose from neutrons was 0.0016 ± 0.0043 Gy in males and 0.0016 ± 0.0050 Gy in females. For those workers who had not been exposed to neutrons, doses from neutrons were not estimated and in the present study they were considered as 'unmeasured 0.00'. The mean unweighted sum of cumulative γ and neutron brain absorbed doses was 0.46 ± 0.67 Gy in males and 0.37 ± 0.56 Gy in females. Distribution of the study cohort workers by radiation dose is presented in Table [S1](#MOESM1){ref-type="media"}.

Statistical analysis {#Sec5}
--------------------

To perform analyses of the data on the study cohort, the statistical techniques and methods were consistent with previous studies^[@CR19]--[@CR21]^. The dataset for analyses was restricted to a period of residence in Ozyorsk, because information on diseases, the results of annual eye examinations and non-radiation factors was unavailable for migrants after they had left the city. This study excluded 43 workers with acute radiation sickness due to acute single high dose-rate γ + neutron exposure, and also excluded 614 workers with missing medical information due to lost medical charts and 77 workers with glaucoma diagnosed prior to employment at the Mayak PA.

As in the previous studies^[@CR19]--[@CR21]^, the analysis provided estimates of relative risk (RR) for categories designated for one or more variables while adjusted for other variables. RR was computed based on maximum likelihood using the AMFIT module of the EPICURE software^[@CR22]^. In order to test a statistical significance, 95% confidence intervals (CIs) for RRs, and *p* values were computed using likelihood-based techniques integrated in the AMFIT module.

In consistence with the previous studies^[@CR19]--[@CR21]^, categorical analyses and dose-response analyses were run using Poisson regression in the AMFIT module of EPICURE software^[@CR19]^. Excess relative risk per unit dose (ERR/Gy) was modeled by a linear trend with dose from external γ-rays, neutron dose and unweighted γ + neutron dose lagged for 5 years including adjustment (via stratification) for non-radiation factors (sex, attained age (\<20, 20--25, ..., 80--85, ≥85 years), birth cohort (\<1910, 1910--1919, 1920--1929, 1930--1939, 1940--1949, ≥1950), hypertension (hypertension-free, hypertension, unknown), body mass index (BMI) (below normal, normal, above normal, obese, unknown), diabetes mellitus (DM) (free from DM, diagnosed with DM) and neutron dose for γ-ray exposure association analysis and vice versa.

Analysis of glaucoma incidence associated with dose from external γ radiation adjusted for neutron dose was set as the default analysis. It considered the whole cohort. The neutron dose adjustment was included using stratification, and the neutron dose was treated as a categorical variable. In consistence with the previous studies^[@CR19]--[@CR21]^, workers who were assumed not to have been exposed to neutrons were not excluded from the analyses; they were included in the 'unmeasured 0.00' category. Analyses of the linear trend with neutron dose and unweighted γ + neutron dose were conducted as sensitivity analyses. The analysis of the linear trend with neutron dose was restricted to workers with measured (or known, or estimated) doses from neutrons (4083 workers). The analysis of the linear trend with unweighted γ + neutron dose considered the whole cohort. To estimate the unweighted γ + neutron dose, the unmeasured neutron dose was regarded as equal to 0.00.

In addition, sensitivity analyses were performed to investigate effects of dose lagging (0, 10, 15, 20-year lag periods) and additional non-radiation factors, such as diagnosed cataract or cataract removal surgery prior to a report of glaucoma, alcohol consumption and smoking status, smoking index (\<10, 10--20, \>20 pack-years) rather than smoking status parameter on the observed risk estimates in relation to external radiation exposure.

Using log-linear modifications of excess relative risk per unit dose we tested whether such factors as sex, age at first employment and attained age of workers could modify the radiation risk of glaucoma incidence. All p-values were for two-sided test. Differences were judged to be significant at *p* \< 0.05.

Since hypertension, BMI and DM are standard risk factor for glaucoma, all these factors were considered in the default analysis (with 5-year lag) via stratification. We excluded these variables as well as the variable of neutron dose, one by one thus investigating the effect of removing these variables from the model.

Definitions and categorizations of risk factors considered in this study are provided in details in Supplementary Section.

Information about whether a worker had a diagnosis of DM and cataract and whether he/she underwent cataract surgery was available for every worker of the study cohort. Cases with cataract and cataract removal surgery were included in the analyses if they were registered before glaucoma was diagnosed in a worker.

An additional analysis was performed to provide odds ratios of various risk factors for primary glaucoma and POAG. The analysis was based on a logit regression and is described in details in Supplementary Section.

Ethical statement {#Sec6}
-----------------

The study was reviewed and approved by the SUBI Institutional Review Board who confirmed that no signed consents were needed from members of the study cohort, because the present record-based epidemiological study did not require any contact with cohort members.

Results {#Sec7}
=======

By the end of the follow-up period, 476 cases of primary glaucoma were registered over 544,236 person-years of follow-up. Of these, RR of glaucoma incidence was calculated each for primary glaucoma and POAG, but not for PACG due to a small number of cases (15 cases).

Risk analysis started with assessment of its associations with known non-radiation factors promoting glaucoma (sex, attained age, smoking, alcohol consumption, cataract and cataract removal surgery, birth cohort, calendar period of diagnosis date, age at first employment, hypertension, BMI, and DM). Tables [2](#Tab2){ref-type="table"} and [S2](#MOESM1){ref-type="media"} summarize the results of the analysis of glaucoma incidence in relation to non-radiation factors.Table 2Risk analysis results for primary glaucoma and POAG incidence in relation to non-radiation factors.FactorsTotal primary glaucomaPOAGRR (95% CI)Number of cases*p* valueRR (95% CI)Number of cases*p* value***RR females vs. males***Males1 (reference)315---1 (reference)307---Females0.68 (0.56, 0.82)161\<0.0010.66 (0.54, 0.81)154\<0.001***RR for various age groups (compared to 65--70 years old group)***Males\<40---0------0---40--450.02 (0.01, 0.04)5\<0.0010.01 (0.01, 0.03)4\<0.00145--500.04 (0.02, 0.08)12\<0.0010.04 (0.02, 0.08)12\<0.00150--550.10 (0.06, 0.15)22\<0.0010.10 (0.06, 0.16)22\<0.00155--600.27 (0.18, 0.39)46\<0.0010.27 (0.18, 0.39)45\<0.00160--650.55 (0.39, 0.76)67\<0.0010.55 (0.40, 0.77)66\<0.00165--701 (reference)81---1 (reference)79---70--751.46 (1.03, 2.06)550.0321.45 (1.01, 2.05)530.04075--801.10 (0.63, 1.81)18\>0.501.14 (0.65, 1.87)18\>0.5080--851.76 (0.77, 3.49)80.1401.59 (0.66, 3.28)70.252≥851.00 (0.06, 4.68)1\>0.501.04 (0.06, 4.83)1\>0.50Females\<40---0------0---40--450.05 (0.01, 0.15)3\<0.0010.02 (0.01, 0.08)1\<0.00145--500.07 (0.02, 0.18)4\<0.0010.07 (0.02, 0.17)4\<0.00150--550.11 (0.04, 0.25)6\<0.0010.07 (0.02, 0.18)4\<0.00155--600.10 (0.03, 0.23)5\<0.0010.10 (0.03, 0.22)5\<0.00160--650.66 (0.40, 1.09)290.1070.62 (0.37, 1.02)280.06265--701 (reference)34---1 (reference)35---70--751.58 (0.99, 2.53)370.0571.50 (0.93, 2.40)360.09375--802.23 (1.35, 3.67)310.0011.96 (1.17, 3.25)280.01080--852.20 (1.01, 4.38)100.0332.38 (1.13, 4.65)110.015≥851.81 (0.29, 6.25)20.4281.85 (0.29, 6.42)20.410***RR for workers diagnosed with vs. without hypertension***MalesUnknown0.78 (0.47, 1.21)190.2940.75 (0.45, 1.19)180.250Hypertension-free1 (reference)247---1 (reference)243---Hypertension0.99 (0.72, 1.34)49\>0.500.95 (0.68, 1.29)46\>0.50FemalesUnknown0.77 (0.41, 1.31)130.3600.81 (0.43, 1.38)130.464Hypertension-free1 (reference)129---1 (reference)123---Hypertension1.00 (0.60, 1.58)19\>0.500.99 (0.58, 1.59)18\>0.50***RR for workers with increased or decreased BMI in relation to workers with normal BMI***MalesUnknown0.97 (0.67, 1.36)36\>0.500.96 (0.66, 1.37)35\>0.50BMI \< 18.5 kg m^−2^0.80 (0.20, 2.09)3\>0.500.81 (0.20, 2.13)3\>0.50BMI 18.5--24.9 kg m^−2^1 (reference)232---1 (reference)227---BMI 25--29.9 kg m^−2^0.77 (0.54, 1.07)390.1350.75 (0.52, 1.04)370.101BMI ≥ 30 kg m^−2^1.09 (0.39, 2.36)5\>0.501.11 (0.40, 2.42)5\>0.50FemalesUnknown0.83 (0.50, 1.32)210.4480.80 (0.48, 1.29)200.383BMI \< 18.5 kg m^−2^---0------0---BMI 18.5--24.9 kg m^−2^1 (reference)83---1 (reference)82---BMI 25--29.9 kg m^−2^1.08 (0.74, 1.55)44\>0.501.00 (0.67, 1.44)40\>0.50BMI ≥ 30 kg m^−2^1.21 (0.64, 2.10)13\>0.501.13 (0.59, 2.00)12\>0.50***RR for workers with vs. without DM***MalesFree from DM1 (reference)293---1 (reference)285---Diagnosed with DM1.35 (0.85, 2.03)220.1821.39 (0.87, 2.10)220.140FemalesFree from DM1 (reference)145---1 (reference)139---Diagnosed with DM1.26 (0.72, 2.06)160.3801.21 (0.68, 2.00)150.488***RR for workers diagnosed with vs. without cataract***MalesFree of cataract1 (reference)89---1 (reference)85---Diagnosed with cataract12.09 (9.08, 16.23)226\<0.00112.56 (9.40, 16.95)222\<0.001FemalesFree of cataract1 (reference)38---1 (reference)32---Diagnosed with cataract8.43 (5.54, 13.19)123\<0.0019.45 (6.09, 15.16)122\<0.001*Notes:* Bold font, *p \< *0.05. BMI, body mass index. CI, confidence interval estimated using the profile likelihood. DM, diabetes mellitus. POAG, primary open-angle glaucoma. RR, relative risk. *p* values are given, assessed via the Wald statistics.

RR for incidence of both primary glaucoma and POAG was significantly lower in females than in males. The incidence risks of primary glaucoma and POAG increased significantly with attained age of workers of both sexes. Incidence of primary glaucoma and POAG was not significantly associated with a calendar period of first employment except for the significantly lower incidence among females hired in 1969--1972 (RR = 0.30 (95% CIs: 0.05, 0.97) and 0.31 (95% CIs: 0.05, 0.99), respectively), which could likely be explained by a small number of cases falling into this group (2 cases). Incidence of primary glaucoma and POAG was significantly associated with certain calendar periods for workers of both sexes. RR for incidence of primary glaucoma and POAG was insignificant in groups of workers by age of first employment at the Mayak PA except for decreased risk in males hired at age 25--30 years compared to those hired before age 20 years. None of smoking status, alcohol consumption status, smoking index and BMI affected incidence of primary glaucoma and POAG in both males and females. Incidence of primary glaucoma and POAG was notably higher in workers diagnosed with cataracts (preceding glaucoma) than those without cataracts: RR in males was 12.09 (95% CIs: 9.08, 16.23) and 12.56 (95% CIs: 9.40, 16.95), respectively; RR in females was 8.43 (95% CIs: 5.54, 13.19) and 9.45 (95% CIs: 6.09, 15.16), respectively. Increased albeit insignificant risk estimates were demonstrated for incidence of primary glaucoma and POAG among workers after cataract removal surgery as well as those with diagnosed DM.

Next, RRs were analyzed for incidence of primary glaucoma and POAG in relation to cumulative dose from external γ-rays, neutrons and γ + neutron exposure. RRs for incidence of primary glaucoma and POAG resulting from all these analyses were insignificant in all dose groups (Table [3](#Tab3){ref-type="table"}). Using a linear model, the primary glaucoma incidence risk, in particular, risk of POAG, was analyzed in relation to external γ-dose (Table [4](#Tab4){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). Incidence of primary glaucoma and POAG was not significantly associated with cumulative dose from external γ-rays, regardless of adjustment for neutron dose with ERR/Gy of 0.01 (95% CIs: −0.13, 0.19) and 0.0003 (95% CIs: −0.13, 0.19) when adjusted and 0.01 (95% CIs: −0.12, 0.20) and 0.01 (95% CIs: −0.13, 0.19) when unadjusted, respectively. Moreover, no significant associations were found with cumulative neutron dose and with cumulative γ + neutron dose for either primary glaucoma or POAG (Table [4](#Tab4){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). Dose lagging (0, 10, 15, 20-year lag periods), inclusion of additional adjustments for non-radiation factors (smoking index, cataract and cataract surgery, smoking status and alcohol consumption) did not significantly modify the observed findings. Exclusion of adjustments for hypertension, BMI and DM did not considerably affect the risk estimate either. Sex, attained age and age at first employment at the enterprise did not significantly modify risk for primary glaucoma (*p* = 0.27, p = 0.38 and p = 0.27, respectively) and for POAG (*p* = 0.28, *p* \> 0.5 and *p* = 0.31, respectively).Table 3RR of primary glaucoma and POAG incidence by dose from external γ-rays, neutron dose and γ + neutron dose.Cumulative dose (Gy), rangeMean cumulative dose (Gy)Total primary glaucomaPOAGPYRNumber of casesRR (95% CI)*p* valuePYRNumber of casesRR (95% CI)*p* value**Baseline analysis (5 year lag)** ^**a**^ **: RR of primary glaucoma and POAG incidence by brain absorbed dose from external γ-rays**0--0.250.06345,3812371 (reference)---345,5122281 (reference)---0.25--0.50.3661,697710.87 (0.65--1.15)0.33261,699700.88 (0.66--1.17)0.3910.5--0.750.6232,775330.76 (0.50--1.10)0.15832,794310.73 (0.48--1.07)0.1210.75--1.00.8723,771350.90 (0.59--1.32)\>0.5023,800350.94 (0.62--1.39)\>0.501.0--1.251.1216,275240.95 (0.58--1.48)\>0.5016,275240.99 (0.60--1.56)\>0.501.25--1.51.3712,744190.90 (0.51--1.47)\>0.5012,765180.91 (0.51--1.50)\>0.501.5--2.01.7217,407331.22 (0.80--1.81)0.34417,409321.22 (0.79--1.82)0.360≥2.02.5715,777240.89 (0.54--1.39)\>0.5015,778230.87 (0.53--1.38)\>0.50**Sensitivity analysis (5 year lag)** ^**b**^ **: RR of primary glaucoma and POAG incidence by brain absorbed dose from neutrons**0--0.0010.000450,538571 (reference)---50,554561 (reference)---0.001--0.00250.001617,990210.78 (0.41, 1.42)0.43817,990210.83 (0.43, 1.51)\>0.500.0025--0.0050.00349,112221.29 (0.65, 2.51)0.4629,130211.20 (0.60, 2.36)\>0.500.005--0.010.00682,88430.34 (0.05, 1.23)0.1582,88430.34 (0.05, 1.22)0.157≥0.010.02241,17832.06 (0.42, 7.37)0.3101,17832.13 (0.43, 7.73)0.292**Sensitivity analysis (5 year lag)** ^**a**^ **: RR of primary glaucoma and POAG incidence by the unweighted sum of brain absorbed γ + neutron dose**0--0.250.06345,3212371 (reference)---345,4412281 (reference)---0.25--0.50.3661,694710.86 (0.65, 1.14)0.31761,700700.88 (0.67, 1.17)0.3940.5--0.750.6232,727330.74 (0.50, 1.07)0.11932,748310.72 (0.48, 1.04)0.0990.75--1.00.8723,787350.99 (0.67, 1.41)\>0.5023,817351.02 (0.69, 1.47)\>0.501.0--1.251.1216,343241.02 (0.64, 1.56)\>0.5016,345241.06 (0.67, 1.61)\>0.501.25--1.51.3712,744190.99 (0.59, 1.57)\>0.5012,765180.97 (0.57, 1.56)\>0.501.5--2.01.7217,428331.14 (0.76, 1.67)\>0.5017,430321.15 (0.75, 1.69)\>0.50≥2.02.5715,783240.86 (0.53, 1.34)\>0.5015,786230.84 (0.51, 1.32)0.476*Notes:* stratified by sex, attained age, birth cohort, diagnosed with hypertension, body mass index, diagnosed with diabetes mellitus and neutron dose for external exposure association analysis and vice versa. CI, confidence interval estimated using the profile likelihood. PYR, person-years at risk. RR, relative risk. POAG, primary open-angle glaucoma. *p* values are given, assessed via the Wald statistics.^a^For all workers.^b^For workers with neutron exposure.Table 4Primary glaucoma and POAG incidence risk with external γ-dose, neutron dose and γ + neutron dose.Analysis typeTotal primary glaucomaPOAGERR/Gy (95% CI)*p* value^a^ERR/Gy (95% CI)*p* value^a^**Incidence risk associated with brain absorbed dose from external γ-rays** ^**i**^Baseline analysis^b^, 5 year lag0.01 (−0.13, 0.19)\>0.500.0003 (−0.13, 0.19)\>0.50**Sensitivity analysis** ^**b**^ **, in which the first x years following the start of radiation work were assigned to a "zero dose" category when lagging doses by x years**0 year lag0.01 (−0.13, 0.19)\>0.500.001 (−0.13, 0.19)\>0.5010 year lag0.002 (−0.13, 0.19)\>0.50−0.003 (−0.14, 0.19)\>0.5015 year lag−0.001 (−0.13, 0.19)\>0.50−0.005 (−0.14, 0.18)\>0.5020 year lag−0.01 (−0.15, 0.17)\>0.50−0.02 (−0.15, 0.17)\>0.50**Sensitivity analysis -- exclusion stratification, 5 year lag:**By hypertension−0.01 (−0.13, 0.17)\>0.50−0.01 (−0.14, 0.17)\>0.50By BMI0.01 (−0.12, 0.19)\>0.500.01 (−0.12, 0.20)\>0.50By diabetes mellitus0.03 (−0.11, 0.22)\>0.500.02 (−0.12, 0.21)\>0.50By neutron dose0.01 (−0.12, 0.20)\>0.500.01 (−0.13, 0.19)\>0.50**Sensitivity analysis -- additional stratification, 5 year lag:**By smoking index0.01 (−0.13, 0.20)\>0.50−0.001 (−0.14, 0.20)\>0.50By smoking and alcohol0.07 (−0.10, 0.32)0.480.06 (−0.11, 0.30)\>0.50By cataract−0.04 (−0.16, 0.12)\>0.50−0.05 (−0.17, 0.11)0.46By cataract surgery0.01 (−0.13, 0.20)\>0.500.004 (−0.13, 0.20)\>0.50**Sensitivity analysis** ^**b**^ **-- analysis restricted to workers, 5 year lag:**Males−0.05 (−0.19, 0.16)\>0.50−0.05 (−0.20, 0.15)\>0.50Females0.16 (−0.13, 0.63)0.380.15 (−0.14, 0.63)0.42*p* value^c^0.270.28**Attained age**\<50 years3.24 (−2.41, 61.08)0.351.22 (−1.35, 57.68)\>0.5050--59 years−0.13 (n/a, 0.41)0.47−0.07 (−0.44, 0.58)\>0.5060--69 years−0.03 (−0.21, 0.26)\>0.50−0.02 (−0.20, 0.28)\>0.50≥70 years0.06 (−0.16, 0.41)\>0.500.02 (−0.20, 0.37)\>0.50*p* value^d^0.38\>0.50*p* value^e^0.49\>0.50**Age at first employment**\<30 years−0.03 (−0.16, 0.18)\>0.50−0.03 (−0.17, 0.17)\>0.5030--40 years−0.19 (n/a, 0.71)0.23−0.18 (n/a, 0.72)0.25≥40 years2.98 (−2.31, 26.99)0.281.81 (−1.55, 17.67)\>0.50*p* value^f^0.270.31**Incidence risk associated with brain absorbed dose from neutrons** ^**j**^Sensitivity analysis^g^, 5 year lag22.83 (−33.20, 150.80)\>0.5023.64 (−33.77, 154.10)\>0.50**Incidence risk associated with the unweighted sum of brain absorbed γ + neutron dose** ^**i**^Sensitivity analysis^h^, 5 year lag0.01 (−0.12, 0.19)\>0.50−0.01 (−0.14, 0.17)\>0.50*Notes:* BMI, body mass index. DM, diabetes mellitus. ERR, excess relative risk. CI, confidence interval estimated using the profile likelihood. n/a, not available. POAG, primary open-angle glaucoma.^a^*p* values of improvement in fit over null model (with no trend in dose) are given, assessed via the Wald statistics.^b^Stratified by sex, attained age, birth cohort, diagnosed with hypertension, BMI, diagnosed with DM and neutron dose.^c^Tested for heterogeneity between males and females, assessed via the likelihood ratio test.^d^Tested for heterogeneity between groups of workers of different attained age, assessed via the likelihood ratio test.^e^Tested for a log-linear trend in the ERR/Gy with attained age, assessed via the likelihood ratio test.^f^Tested for heterogeneity between groups of workers of different age at first employment, assessed via the likelihood ratio test.^g^Stratified by sex, attained age, birth cohort, diagnosed with hypertension, BMI, diagnosed with DM and dose from external γ-ray.^h^Stratified by sex, attained age, birth cohort, diagnosed with hypertension, BMI, diagnosed with DM.^i^For all workers.^j^For workers with neutron exposure.Figure 1Primary glaucoma (**a**,**c**,**e**) and POAG (**b**,**d**,**f**) incidence by cumulative dose from external γ-rays (**a**,**b**), neutron dose (**c**,**d**) and γ + neutron dose (**e**,**f**).

Results of the additional analysis providing odds ratios of various risk factors for primary glaucoma and POAG using the logit regression are summarized in Table [S3](#MOESM1){ref-type="media"}. The analysis demonstrated that its results are in good agreement with the results of the analyses based on the Poisson regression described above.

Discussion {#Sec8}
==========

This is a retrospective cohort study with a number of advantages, such as the large size of the study cohort, information on both sexes (with 25.4% of females), the extensive follow-up period (up to 70 years), availability of medical information and data on non-radiation risk factors over the entire follow-up period. The main advantage of the present study are the mandatory annual health examinations over the entire follow-up. The annual health examinations were performed using a standard protocol and included a mandatory check by an ophthalmologist and an ophthalmological examination using conventional techniques regardless of workers' sex, age, working site, occupation, radiation dose, etc.

As expected, the present study found significant associations between primary glaucoma and some known non-radiation risk factors such as sex, attained age, cataract diagnosed before glaucoma manifestation, and cataract removal surgery. These results are in line with those observed in other studies^[@CR3],[@CR4],[@CR23]--[@CR25]^.

The present study did not reveal any significant associations between primary glaucoma incidence and doses from external γ + neutron radiation exposure and its separate components (γ-rays, neutrons) whether adjusted for each other or not. Further one-by-one exclusion of known risk factors (hypertension, BMI, DM) in the model did not modify the ERR/Gy estimate either for primary glaucoma or for POAG (Table [4](#Tab4){ref-type="table"}). While investigating effects following fractionated exposures at dose above tens Gy (each fraction delivered at high dose rate), a number of studies have demonstrated neovascular glaucoma as one of the normal tissue complications following ocular or head and neck radiotherapy, which have been mediated by plaque formation in microcirculation and further neovascularization^[@CR5]--[@CR11]^. As shown in Table [5](#Tab5){ref-type="table"}, following single, acute exposure at several Gy, glaucoma risk has been reported in Japanese atomic bomb survivors: Yamada *et al*. first reported that incidence of glaucoma in aggregate (i.e., without distinguishing any type of glaucoma) significantly decreases with increasing radiation dose^[@CR26]^. In a subsequent study, and as shown in Table [5](#Tab5){ref-type="table"}, Kiuchi *et al*. reported an Odds ratio at 1 Gy of 1.31 (95% CIs: 1.11, 1.53, *p* = 0.001) for normal-tension glaucoma, albeit with no significant associations between radiation doses and other types of glaucoma^[@CR12]^, and the authors in their recent paper^[@CR13]^ confirmed the significant odds ratio at 1 Gy for NTG for both right and left eyes (Table [5](#Tab5){ref-type="table"}). However, Kiuchi *et al*.^[@CR12]^ note that it was a screening study and the cohort member participation rate in that study was relatively low, underlining a need to interpret these findings with caution. Following occupational protracted exposures at low dose, there was no literature available until Little *et al*. very recently reported an insignificantly decreased risk for self-reported glaucoma in aggregate in the US radiologic technologists (USRT) cohort^[@CR14]^ (and see also Table [5](#Tab5){ref-type="table"}), which was based solely on questionnaire information obtained from medically literate workers, without any ophthalmological validation. Accordingly, it remains unclear whether members of the USRT cohort and Mayak workers exhibit a significantly increased risk for normal-tension glaucoma as reported in atomic bomb survivors. As such, our future studies include evaluation of the POAG risk separately for normal-tension type and high-tension type based on the measured IOP data.Table 5Glaucoma incidence risk following various exposure scenarios.Reference, yearStudy designCohortFollow-up periodRadiation dose (range)Number of participantsNumber of casesFindingsAdjustmentsKiuchi *et al*.^[@CR12]^Screening with the succeeding ophthalmological examinationAHS2006--2008(51--53 yearsafter exposure)Eye dose0.57 Gy(0--4.14)1589Normal-tensionPOAG: 226OR at 1 Gy = 1.31(95% CIs: 1.11, 1.53,*p* = 0.001)Sex, age, city, cataract surgery, diabetes mellitusPOAG with IOP \> 21 mmHg: 36OR at 1 Gy = 0.79(95% CIs: 0.52, 1.21,*p* = 0.28)PACG: 25OR at 1 Gy = 0.54(95% CIs: 0.29, 1.02,*p* = 0.06)Kiuchi *et al*.^[@CR13]^Screening with the succeeding ophthalmological examinationAHS2006--2008(51--53 yearsafter exposure)Mean radiation dose0.66 Gy(NTG subjects)1640NTG: 153OR at 1 Gy = 1.39(95% CI: 1.15, 1.69,*p* \< 0.01)Sex. Age, city, smoking, hypertension, dyslipidemia, diabetes, BMI, CRPPOAG: 25OR at 1 Gy = 0.79(95% CI: 0.32, 1.82,*p* = 0.54)PACG: 18OR at 1 Gy = 0.44(95% CI: 0.13, 1.54,*p* = 0.20)Little *et al*.^[@CR14]^Questionnaire-based screening (self-reported diagnosis)USRT1983--19891994--19982003--20052012--2014(13.2 years of amean follow-upper person)Eye lens dose0.058 Gy(0.024--0.071)69,5681631ERR/Gy = −0.57(95% CIs: −1.46, 0.60,*p* = 0.304)Sex, ethnicity, year of birth, diabetes mellitus, BMI, smoking statusAzizova *et al*., 2019 (present study)Cohort study based on mandatory annual ophthalmological examinations throughout the whole follow-up periodMayak PA1948--2008(35.7 years of amean follow-upper person)Brain absorbeddosefrom externalγ-rays 0.44 Gy(0--8.4)22,377Primaryglaucoma: 476ERR/Gy = 0.01(95% CIs: −0.13, 0.19,*p* \> 0.50)Sex, attained age, birth cohort, hypertension, BMI, DM and neutron dosePOAG: 461ERR/Gy = 0.0003(95% CIs: −0.13, 0.19,*p* \> 0.50)AHS, Adult Health Study. BMI, body mass index, CRP, C-reactive protein. DM, diabetes mellitus. ERR, excess relative risk. IOP, intraocular pressure. OR, odds ratio. PA, Production Association. PACG, primary angle-closure glaucoma. POAG, primary open-angle glaucoma. USRT, US Radiologic Technologists.

Biological mechanisms underlying radiation-induced glaucoma remain unclear^[@CR27]^. The most likely mechanisms that have been suggested thus far involve impaired retinal circulation since some data have demonstrated the impaired circulation at 30--45 years after radiation exposure^[@CR28]^ as well as retinal vessel atherosclerosis^[@CR29]^. In addition, other possible mechanisms of radiation glaucoma may include neural excitotoxicity^[@CR30]^, inflammation^[@CR31]^, genetic predisposition^[@CR32]--[@CR35]^, autoimmune reactions^[@CR36]^ and retinal circulation disorders^[@CR37],[@CR38]^. Some investigators believe that the most likely of them might be retinal circulation disorders^[@CR12]^, since there is evidence of radiation-induced blood flow decrease in the retina 30 or 45 years after the exposure^[@CR28]^, as well as of the significant association of retinal arteriosclerosis with radiation exposure in atomic bomb survivors 55 years after the exposure^[@CR29]^.

In conclusion, significant association was found neither between cumulative dose from external γ-rays nor cumulative neutron dose nor the unweighted sum of cumulative γ and neutron doses and incidence of primary glaucoma and POAG in the cohort of Mayak PA workers. Glaucoma incidence was significantly associated with non-radiation risk factors (sex, attained age, and cataract diagnosed prior to glaucoma). Further analyses to distinguish normal-tension type and high-tension type are needed.
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